A multicenter study involving 104 patients demonstrated that ustekinumab is more effective and durable than vedolizumab in treating Crohn's disease of the pouch, which can occur post-surgery for ulcerative colitis. The study included adults who underwent colectomy followed by ileal pouch-anal anastomosis (IPAA). Over median follow-ups of 2.5 years for ustekinumab and 3.1 years for vedolizumab, 62% of patients on ustekinumab showed a clinical response at 3 months versus 53% on vedolizumab. Though both treatments were effective and well-tolerated, ustekinumab exhibited superior clinical response and treatment persistence, indicating a potential for earlier use in treatment protocols.

Source: Inflammatory Bowel Diseases